Cytochrome P450 3A inhibitors and enhancers

Details Cytochrome P450 3A inhibitors and enhancers Cytochrome P450 3A inhibitors and enhancers

2007-01-30

2007-01-30

Spivack, Phyllis G. (Department: 1614)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

Reexamination Certificate

active

10080043

ABSTRACT:
The present invention provides cytochrome P450 3A (CYP3A) inhibitors and enhancers. Examples of the CYP3A inhibitors include free bases or pharmacologically acceptable salts of at least one of the following compounds: α-naphthoflavone, β-naphthoflavone, apigenin, baicalein, β-myrcene, catechin, 3-phenylpropyl acetate, formononetin, gallic acid, hesperetin, hesperidin, isoquercitrin, lauryl alcohol, luteolin, luteolin-7-glycoside, narigin, nordihydroguaiaretic acid, quercitrin, swertiamarin, terpineol, and trans-cinnamaldehyde. Examples of the CYP3A enhancers include free bases or pharmacologically acceptable salts of at least one of the following compounds: apigenin, formononetin, and luteolin-7-glycoside. The CYP3A inhibitors can be used, alone or co-administered with a drug, to improve the drug bioavailability. The CYP3A inhibitors can also be used as chemopreventors to prevent biotransformation of procarcinogenic compounds into carcinogens via CYP3A activity or for treatment of intestinal or hepatic cancer by inhibit the CYP3A activity. The CYP3A enhancers can be used to improve the enzymatic activity of CYP3A so as to improve the biotransformation and degradation of active drugs or the sustrates of CYP3A from the body. The CYP3A inhibitors and enhancers of the present invention are natural substances extracted from herbs and non-toxic.

REFERENCES:
patent: 5229116 (1993-07-01), Edgar et al.
patent: 5478723 (1995-12-01), Parkinson et al.
patent: 5567592 (1996-10-01), Benet et al.
patent: 5665386 (1997-09-01), Benet et al.
patent: 5716928 (1998-02-01), Benet et al.
patent: 5916566 (1999-06-01), Benet et al.
patent: 5962522 (1999-10-01), Wacher et al.
patent: 6004927 (1999-12-01), Benet et al.
patent: 6028054 (2000-02-01), Benet et al.
patent: 6063809 (2000-05-01), Harris
patent: 6121234 (2000-09-01), Benet et al.
patent: 6160006 (2000-12-01), Edwards et al.
patent: 6180666 (2001-01-01), Wacher et al.
patent: 6509371 (2003-01-01), He et al.
patent: 2002/0128282 (2002-09-01), Schellens et al.
Yamahara et al., Journal of Ethnopharmacology, (1991) 33(1-2), pp. 31-36 (abstract).
Yamahara et al., Yakugaku Zasshi (1998), 98(11), 1446-51 (abstract).
Lei et al., Zhongcaoyao (1982), 13(8), 368-9 (abstract).
Hikino et al., Shoyakugaku Zasshi (1984), 38(4), 359-60 (abstract).
Kai S. Lee; Ibutilide, a New Compound with Potent Class III Antiarrhythmic Activity, Activates a Slow Inward Na+ Current in Guinea Pig Ventricular Cells; The Journal of Pharmacology and Experimental Therapeutics, 1992, p. 99-108, vol. 262, No. 1.
Ilya B. Tsyrlov et al.; Isozyme-and species-specific susceptibility of cDNA-expressed CYP1A P-450s to different flavonoids; Biochimica et Biophysica Acta, 1994, p. 325-335, vol. 1205.
Aleksandra Pastrakuljic et al.; Distinction of CYP1A1 and CYP1A2 Activity by Selective Inhibition Using Fluvoxamine and Isosafrole; Biochemical Pharmacology, 1997, p. 531-538, vol. 53.
Henry P. Ciolino et al.; Dietary flavonols quercetin and kaempferol are ligands of the aryl hydrocarbon receptor that affect CYP1A1 transcription differentially; Biochemical Society, 1999, p. 715-722, vol. 340.
Jukka Maenpaa et al.; Differential Inhibition of Coumarin 7-Hydroxylase Activity in Mouse and Human Liver Microsomes; Biochemical Pharmacology, 1993, p. 1035-1042, vol. 45.
R. Edenharder et al.; The inhibition by flavonoids of 2-amino-3-methylimidazo[4,5-f]quinoline metabolic activation to a mutagen: a structure-activity relationship study; Mutation Research, 1997, p. 21-32, vol. 379.
Wen-Shing Chang et al.; Inhibitory Effects of Flavonoids on Xanthine Oxidase; Anticancer Research, 1993, p. 2165-2170, vol. 13.
A. Galijatovic et al.; Extensive metabolism of the flavonoid chrysin by human Caco-2 and Hep G2 cells; Xenobiotica, 1999, p. 1241-1256, vol. 29, No. 12.
Hroshi Yamazaki et al.; Highly sensitive high-performance liquid chromatographic assay for coumarin 7-hydroxylation and 7-ethoxycoumarin O-deethylation by human liver cytochrome P450 enzymes; Journal of Chromatography B, 1999, p. 13-19, vol. 721.
M.T. Obermeier et al.; Effects of bioflavonoids on hepatic P450 activities; Xenobiotica, 1995, p. 575-584, vol. 25.
S.E. Nielsen et al.; In vitro biotransformation of flavonoids by rat liver microsomes; Xenobiotica, 1998, p. 389-401, vol. 28, No. 4.

Affiliated with

Also associated with

Rating

Cytochrome P450 3A inhibitors and enhancers does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cytochrome P450 3A inhibitors and enhancers, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cytochrome P450 3A inhibitors and enhancers will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3764642